Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N3BB
|
|||
| Former ID |
DIB008620
|
|||
| Drug Name |
CBX-129801
|
|||
| Synonyms |
Ersatta; C-peptide (depot formulation), Cebix; Long-acting synthetic C-peptide, Cebix; PEGylated C-peptide (diabetic complications), Cebix
Click to Show/Hide
|
|||
| Indication | Diabetic complication [ICD-11: 5A2Y; ICD-10: E08-E13] | Phase 2 | [1] | |
| Company |
Cebix
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Connecting peptide (C-peptide) | Target Info | Modulator | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01681290) Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.